COCH
Envoy Medical, Inc.
There isn't enough reported data to score COCH yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
COCH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Strong |
COCH's balance sheet is currently strong, and its revenue is stable, but its profitability is weak. There isn't enough data to rate its cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
COCH PE Valuation
COCH has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
COCH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect COCH's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
COCH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.70 | +$10.20 |
| Q2 2026 | -$7.70 | +$7.40 |
| Q1 2026 | -$10.20 | +$4.40 |
| Q4 2025 | -$12.30 | +$2.60 |
COCH is still losing money, but far less than before: $4.70 per share over the past year, against $15.10 at its worst in mid-2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over COCH on earnings quality, reporting a profit while its opponent remains loss making.
COCH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $66K | +57% |
| Q2 2026 | $51K | -35% |
| Q1 2026 | $39K | -15% |
| Q4 2025 | $75K | +79% |
| Q3 2025 | $42K | -25% |
| Q2 2025 | $78K | +15% |
| Q1 2025 | $46K | -22% |
| Q4 2024 | $42K | -56% |
COCH's revenue is recovering but still below its 2023 peak: $66,000 last quarter, up 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8389% | +5201 points |
| Q2 2026 | -10920% | -4420 points |
| Q1 2026 | -15279% | -4177 points |
| Q4 2025 | -8513% | +2258 points |
| Q3 2025 | -13590% | -4708 points |
| Q2 2025 | -6500% | +647 points |
| Q1 2025 | -11102% | -2801 points |
| Q4 2024 | -10771% | -3682 points |
COCH's operating margin was −8389% last quarter, up 5201 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over COCH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over COCH on profitability, with a higher operating margin.
COCH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.1M | -$726K |
| Q4 2025 | -$5.9M | -$2M |
| Q3 2025 | -$4.3M | -$367K |
| Q4 2024 | -$3.9M | +$7.9M |
COCH has burned cash in almost every quarter: −$20M over the past year, against −$23M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
COCH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +30.6K shares |
| 1 year | +378% | +8.2M shares |
| 3 years | +96% | +5.1M shares |
COCH has 10M diluted shares, up 378% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over COCH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
COCH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -0.0x | Net Cash |
| Q3 2021 | -0.1x | Net Cash |
COCH has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
COCH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 62.7 | Neutral |
COCH's weekly RSI is 49 (neutral) and its Stochastic is 63 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
COCH PE vs Healthcare Sector
| Metric | COCH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
COCH has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
COCH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.72 | 1.3% above |
| 20 week MA | $6.96 | 2.2% below |
| 50 week MA | $6.90 | 1.3% below |
| 100 week MA | $10.1 | 33% below |
| 200 week MA | $32.4 | 79% below |
COCH has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over COCH on trend strength, trading above more of its moving averages.
COCH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $97.5 | $97.4 | -0.1% |
| 2022 | $97.4 | $99.7 | +2.4% |
| 2023 | $99.7 | $18.1 | -82% |
| 2024 | $18.1 | $16.0 | -12% |
| 2025 | $16.0 | $7.30 | -54% |
| 2026 YTD | $7.30 | $6.81 | -6.7% |
COCH has finished three years in a row lower, and it's down 6.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over COCH on returns for 2026, with the stronger performance.